Global Wilson’s disease treatment market, by Treatment Medications (D-Penicillamine, Trientine, Zinc, Tetrathiomolybdate), Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Government bodies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 527.0 Million in 2022 and is expected to exhibit a CAGR of 6.2% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Increasing initiatives by key player to provide affordable drugs for Wilson’s disease treatment is expected to drive the market growth over the forecast period. For instance, in May 2022, Laurus Labs, an Indian multinational pharma and biotech company is planning to introduce the affordable drug for the treatment of Wilson’s disease in the India market.
Global Wilson’s disease Treatment Market – Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions.
The supply and distribution of Wilson’s disease drugs has been negatively impacted due to the COVID-19 lockdown and restrictions. For instance, according to an article published by U.S. National Library Of Medicines, National Institute of Health, in Feburary 2022 , the patients with Wilson’s disease usually have a follow-up of treatment (ultrasound of the liver ,clinical examination, urine and blood samples) every six months in the maintenance phase of the disease got destabilized. These brought disturbance in the treatment due to covid-19 has negative effect on market of Wilson’s disease medication. Several manufacturers of Wilson’s disease drug are facing issues such as a shortage of labor and transportation of raw materials, which has affected the production of Wilson’s disease drugs. Most of the vehicles used for transportation of these products are stuck at the state borders or at the country borders.
Therefore, during the COVID-19 pandemic, there was high demand for Wilson’s disease drugs , but as the supply chain was disrupted, there was a shortage in the availability of Wilson’s disease medication, which hampered growth of market.
Recent Development in Wilson’s disease Treatment Market:
In August 2021, AstraZeneca announced positive results regarded to phase III study ofALXN1840 in patients with the rare genetic disorder. ALXN1840 is a potential is oral medicine designed to be the first targeted de-coppering therapy.
Browse 25 Market Data Tables and 29 Figures spread through 185 Pages and in-depth TOC on “Global Wilson’s Disease Treatment Market”- Forecast to 2030, Global Wilson’s Disease Treatment Market, by Treatment (Medications (D-Penicillamine, Trientine, Zinc, Tetrathiomolybdate), Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Government bodies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in Wilson’s disease treatment market, click the link
https://www.coherentmarketinsights.com/market-insight/wilsons-disease-treatment-market-526
Moreover, increasing research and development for wilson’s disease drugs is expected to drive the market growth over the forecast period. For instance, according to data published by Pfizer Inc. in August 2021, Vivet’s second gene therapy product, VTX-803 for PFIC3, obtained European and US Orphan Drug Designation in May 2020. VTX-801 for the treatment of Wilson disease had got the Fast Track designation from Food and Drug Administration (FDA). Fast Track is a process outlined to facilitate the development, expedite the review of, drugs to treat serious reactions that address a superficial medical need, by providing a therapy where none exists or providing a therapy which may be potentially better and give some benefits over available therapy.VTX-801 is a novel replication-deficient recombinant adeno-associated viral vector (rAAV) gene therapy that contains a single-stranded DNA genome with a shortened version of the ATP7B gene.
Key Takeaways of the Global Wilson’s Disease Treatment Market:
- Global wilson’s disease treatment market is expected to exhibit a CAGR of 6.2% during the forecast period, due to increasing inorganic growth strategies such as partnership to increase production of Wilson’s disease drugs by key players. For instance, in November 2020, the partnership between Deep Genomics, a Toronto-based in Canada artificial intelligence (AI) company and BioMarin, world leader in developing and commercializing innovative biopharamceutics for rare diseases had discover and develop oligonucleotide drug candidates for four rare diseases which included Wilson’s disease.
- Among Medication type segment, the Trientine segment is estimated to hold a dominant position in the global Wilson’s disease treatment market over the forecast period, owing to increased research and development for Wilson’s disease drugs. For instance, Orphalan SA, a company that develops, identifies and delivers innovative treatments to patients with rare diseases, announced positive top line data with Trientine Tetrahydrochloride for maintenance patients with Wilson’s disease. CHELATE study trial confirmed that trientine tetrahydrochloride was non-inferior to d-Penicillamine as well as Trientine tetrahydrochloride was well supported and accepted during treatment of Wilson’s disease.
- Major players operating in the global wilson’s disease treatment market include Valeant Pharmaceuticals International, Inc., Noblepharma Co., Ltd., Wilson Therapeutics AB, Kadmon Holdings, Inc., Merck & Co., Inc., VHB Life Science Ltd., Teva Pharmaceuticals USA, Inc., and Tsumura & Co.
